Sutro Biopharma Earlier Announced Luvelta Demonstrated Encouraging Preliminary Anti-Tumor Activity (29% Response Rate) In Late-stage Patients With Recurrent/relapsed Endometrial Cancer With Tumor Proportion Score (TPS) >25% Folrα Expression
Portfolio Pulse from Charles Gross
Sutro Biopharma announced initial results from a Phase 1 dose-expansion study of luveltamab tazevibulin (luvelta), a novel Folate receptor alpha (FolRα)-targeting ADC, in patients with endometrial cancer. The study showed encouraging preliminary anti-tumor activity in patients with FolRα-expressing endometrial cancer. In patients with TPS >25% FolRα expression, a confirmed partial response was seen in 29% of cases, and the Disease Control Rate was 86%.
October 22, 2023 | 3:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sutro Biopharma's luveltamab tazevibulin shows promising results in Phase 1 study for endometrial cancer. This could potentially boost the company's reputation and stock value.
The positive preliminary results from the Phase 1 study of luveltamab tazevibulin, a novel drug by Sutro Biopharma, could potentially increase investor confidence in the company, leading to a rise in its stock value. The promising anti-tumor activity demonstrated by the drug in endometrial cancer patients could also enhance the company's reputation in the oncology field.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100